2013 Nucleosides, Nucleotides, and Oligonucleotides Gordon Research Conference

2013年核苷、核苷酸和寡核苷酸戈登研究会议

基本信息

  • 批准号:
    8519771
  • 负责人:
  • 金额:
    $ 0.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-24 至 2013-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal requests partial support for a meeting on Nucleosides, Nucleotides, and Oligonucleotides as part of the Gordon Research Conference series to be held in Salve Regina University, Newport, RI from June 30, to July 5, 2013. The broad and long term goal of the conference is to increase our understanding of the chemistry and biology of nucleosides, nucleotides, and oligonucleotides. The specific aims of this meeting will be to convene nine discussion leaders to moderate nine sessions. A chair and vice-chair will supervise the whole conference. There will be a total of 29 invited speakers who will represent critical areas of the chemistry and biology of nucleosides, nucleotides, and oligonucleotides and 8 oral student/postdoctoral presentations. The program will have a keynote lecture and nine sessions that broadly address current issues in nucleic acid chemistry, DNA repair, discovery of anticancer and antiviral agents, synthetic biology, nucleotide metabolism in bacteria, enzymology of purine and pyrimidine metabolism, and RNA metabolism. The keynote lecture will be given by Dr. Thomas Steitz, who won the Nobel Prize in Chemistry in 2009 for his work on the structure and function of the ribosome. In addition, two evening poster sessions will permit all participants to contribute to the meeting. As with all Gordon Conferences there will be numerous opportunities for young investigators, women, and minorities to interact with senior leaders in the field. The significance of this application is that the Gordon Research Conference is the only platform where chemists and biologists who focus on nucleosides, nucleotides, and oligonucleotides come together. Nucleoside analogs, acting by diverse mechanisms, are highly effective for the treatment of cancer and several viral diseases including AIDS. In addition, nucleic acids analogs as siRNA, miRNA, antisense, catalytic RNA belong to one of the most exciting new areas in drug development. Besides becoming major tools for prognosis and diagnosis of various diseases, oligonucleotides are also used as new tools in epigenetics, synthetic biology and systems chemistry, which will become important technologies for generating new drugs for the future. The conference will focus on all these new areas and will be a discussion forum and an exchange platform for generating new knowledge and collaborations. This conference is therefore highly significant regarding its health relatedness, as the discussions among chemists and biologists will generate new knowledge and avenues for development of novel therapeutics.
描述(由申请人提供):本提案请求部分支持将于2013年6月30日至7月5日在RI纽波特的Salve Regina大学举行的关于核苷、核苷酸和寡核苷酸的会议,作为戈登研究会议系列的一部分。会议的广泛和长期目标是增加我们对核苷、核苷酸和寡核苷酸的化学和生物学的了解。本次会议的具体目标是召集9位讨论领袖主持9场会议。一名主席和一名副主席将监督整个会议。共有29名受邀演讲者将代表核苷、核苷酸和寡核苷酸化学和生物学的关键领域,并将有8名学生/博士后口头报告。该计划将有一次主旨演讲和九次会议,广泛讨论当前的问题,包括核酸化学、DNA修复、抗癌和抗病毒药物的发现、合成生物学、细菌中的核苷酸代谢、嘌呤和嘧啶代谢的酶学以及RNA代谢。主旨演讲将由托马斯·斯泰茨博士主持,他因在核糖体结构和功能方面的工作而获得2009年诺贝尔化学奖。此外,两次晚间海报会议将允许所有与会者为会议做出贡献。与所有戈登会议一样,年轻的研究人员、女性和少数族裔将有许多机会与该领域的高级领导人互动。这一应用的意义在于,戈登研究会议是专注于核苷、核苷酸和寡核苷酸的化学家和生物学家聚集在一起的唯一平台。核苷类似物通过不同的作用机制,对癌症和包括艾滋病在内的几种病毒疾病的治疗非常有效。此外,siRNA、miRNA、反义、催化RNA等核酸类似物属于药物开发中最令人兴奋的新领域之一。寡核苷酸除了成为预测和诊断各种疾病的主要工具外,还被用作表观遗传学、合成生物学和系统化学的新工具,将成为未来产生新药的重要技术。会议将聚焦于所有这些新领域,并将成为一个讨论论坛和交流平台,以产生新的知识和合作。因此,这次会议具有非常重要的意义,因为化学家和生物学家之间的讨论将产生新的知识和新的治疗方法的发展途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM B PARKER其他文献

WILLIAM B PARKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM B PARKER', 18)}}的其他基金

2011 Nucleosides, Nucleotides, and Oligonucleotides GRC
2011 核苷、核苷酸和寡核苷酸 GRC
  • 批准号:
    8116777
  • 财政年份:
    2011
  • 资助金额:
    $ 0.5万
  • 项目类别:
MECHANISM OF ACTION OF NUCLEOSIDE ANALOGS
核苷类似物的作用机制
  • 批准号:
    6563810
  • 财政年份:
    2002
  • 资助金额:
    $ 0.5万
  • 项目类别:
Purine Analog Anti-Mycobacterial Drug Development
嘌呤类似物抗分枝杆菌药物开发
  • 批准号:
    7232669
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
PURINE ANALOG ANTIMYCOBACTERIAL DRUG DEVELOPMENT
嘌呤类似物抗真菌药物的开发
  • 批准号:
    2797353
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
BIOCHEMISTRY OF PURINE NUCLEOSIDE ANALOGS ACTIVATED BY E COLI PNP
大肠杆菌 PNP 激活的嘌呤核苷类似物的生物化学
  • 批准号:
    6203306
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
Purine Analog Anti-Mycobacterial Drug Development
嘌呤类似物抗分枝杆菌药物开发
  • 批准号:
    7609201
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
Purine Analog Anti-Mycobacterial Drug Development
嘌呤类似物抗分枝杆菌药物开发
  • 批准号:
    7012750
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
Purine Analog Anti-Mycobacterial Drug Development
嘌呤类似物抗分枝杆菌药物开发
  • 批准号:
    6947999
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
PURINE ANALOG ANTIMYCOBACTERIAL DRUG DEVELOPMENT
嘌呤类似物抗真菌药物的开发
  • 批准号:
    6341712
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:
Purine Analog Anti-Mycobacterial Drug Development
嘌呤类似物抗分枝杆菌药物开发
  • 批准号:
    7410131
  • 财政年份:
    1999
  • 资助金额:
    $ 0.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了